Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil

Details

Serval ID
serval:BIB_BC6FF3988709
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil
Journal
Clinical Therapeutics
Author(s)
Nussberger  J., Koike  H.
ISSN
0149-2918 (Print)
Publication state
Published
Issued date
2004
Volume
26 Suppl A
Pages
A12-20
Notes
Journal Article
Review
Abstract
BACKGROUND: The orally active, nonpeptide antagonists of the angiotensin II subtype 1 (AT1) receptor represent a recent class of antihypertensive drugs that selectively block the renin-angiotensin system. Olmesartan medoxomil is the newest member of this class. OBJECTIVE: This article reviews the renin-angiotensin system and how this system can be pharmacologically inhibited by the selective antagonists of the AT1 receptor, with a main focus on the AT1 receptor antagonist olmesartan. METHODS: Key studies were selected from previous work to illustrate the antihypertensive, cardioprotective, and renoprotective effects of olmesartan, and to compare class effects of AT1 receptor antagonists and angiotensin-converting enzyme (ACE) inhibitors. RESULTS: Olmesartan, the active metabolite of olmesartan medoxomil, is a highly potent antagonist of the AT1 receptor. It inhibits the contractile responses to angiotensin II in guinea pig aorta, inhibits the pressor responses to angiotensin II in rats and dogs, and exhibits dose-dependent antihypertensive effects in spontaneously hypertensive rats. In addition to its antihypertensive effects, olmesartan medoxomil provides protection against cardiac and renal damage in animal models. AT1 receptor antagonists are more specific inhibitors of the renin-angiotensin system compared with ACE inhibitors. They are well tolerated and have an excellent safety profile. Unlike angiotensin-converting enzyme inhibitors, AT1 receptor antagonists lack the nonangiotensin-related side effects such as cough and angioedema. CONCLUSIONS: AT1 receptor antagonists such as olmesartan represent a valid therapeutic option for the treatment of hypertension and other cardiovascular and renal diseases.
Keywords
Angioneurotic Edema/chemically induced *Angiotensin II Type 1 Receptor Blockers Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use Animals Antihypertensive Agents/adverse effects/*pharmacology/therapeutic use Clinical Trials Cough/chemically induced Humans Imidazoles/adverse effects/*pharmacology/therapeutic use Receptor, Angiotensin, Type 1/metabolism Renin-Angiotensin System/drug effects/physiology Tetrazoles/adverse effects/*pharmacology/therapeutic use
Pubmed
Web of science
Create date
05/03/2008 17:40
Last modification date
20/08/2019 16:30
Usage data